Screening and mechanistic study of natural compounds that enhance T cell anti-tumor effects post-heat treatment

Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 16; p. 1537398
Main Authors Wang, Zhaoyi, Diao, Zhongqi, Zhang, Yiyan, Liu, Jiangying, Li, Yeshan, Sun, Zijin, Zhen, Huimin, Wang, Haojia, Yang, Siyun, Wang, Tieshan, Ni, Lei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 27.03.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under culture conditions represents a current hot research topic in this domain. In the current experiment, we conducted heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action. The findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways.
AbstractList IntroductionFollowing the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under in vitro culture conditions represents a current hot research topic in this domain.MethodsIn the current experiment, we conducted in vitro heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action.Results and DiscussionThe findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways.
Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under culture conditions represents a current hot research topic in this domain. In the current experiment, we conducted heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action. The findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways.
Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under in vitro culture conditions represents a current hot research topic in this domain.IntroductionFollowing the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under in vitro culture conditions represents a current hot research topic in this domain.In the current experiment, we conducted in vitro heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action.MethodsIn the current experiment, we conducted in vitro heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action.The findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways.Results and DiscussionThe findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways.
Author Diao, Zhongqi
Zhang, Yiyan
Yang, Siyun
Li, Yeshan
Wang, Haojia
Liu, Jiangying
Wang, Tieshan
Wang, Zhaoyi
Zhen, Huimin
Sun, Zijin
Ni, Lei
AuthorAffiliation 3 School of Life Sciences, Beijing University of Chinese Medicine , Beijing , China
5 Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine , Beijing , China
4 School of Chinese Materia Medica, Beijing University of Chinese Medicine , Beijing , China
2 Department of Cancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University , Urumqi , China
1 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine , Beijing , China
AuthorAffiliation_xml – name: 3 School of Life Sciences, Beijing University of Chinese Medicine , Beijing , China
– name: 4 School of Chinese Materia Medica, Beijing University of Chinese Medicine , Beijing , China
– name: 1 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine , Beijing , China
– name: 2 Department of Cancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University , Urumqi , China
– name: 5 Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine , Beijing , China
Author_xml – sequence: 1
  givenname: Zhaoyi
  surname: Wang
  fullname: Wang, Zhaoyi
– sequence: 2
  givenname: Zhongqi
  surname: Diao
  fullname: Diao, Zhongqi
– sequence: 3
  givenname: Yiyan
  surname: Zhang
  fullname: Zhang, Yiyan
– sequence: 4
  givenname: Jiangying
  surname: Liu
  fullname: Liu, Jiangying
– sequence: 5
  givenname: Yeshan
  surname: Li
  fullname: Li, Yeshan
– sequence: 6
  givenname: Zijin
  surname: Sun
  fullname: Sun, Zijin
– sequence: 7
  givenname: Huimin
  surname: Zhen
  fullname: Zhen, Huimin
– sequence: 8
  givenname: Haojia
  surname: Wang
  fullname: Wang, Haojia
– sequence: 9
  givenname: Siyun
  surname: Yang
  fullname: Yang, Siyun
– sequence: 10
  givenname: Tieshan
  surname: Wang
  fullname: Wang, Tieshan
– sequence: 11
  givenname: Lei
  surname: Ni
  fullname: Ni, Lei
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40213558$$D View this record in MEDLINE/PubMed
BookMark eNpVUk1vGyEQRVWiJnXzB3qoOPayLp_r3VNVRc2HFKmHJmeEh8HeaBdcYCvl3xfHTpRwgBG8eW9meJ_ISYgBCfnC2VLKrv_uh2mal4IJveRarmTffSDnvG1VI4VQJ2_iM3KR8yOrS_VSSv2RnCkmuNS6OyfxDyTEMIQNtcHRCWFrw5DLADSX2T3R6GmwZU52pBCnXZyDy7RsbaEYKhSQ3lPAcazpZWjKPMVE0XuEkuku5tJssWJLqvuEoXwmp96OGS-O54I8XP26v7xp7n5f317-vGtACVEap70A51uUoheM-zUAt0LorkcHrIUVR66tsqAYOKm070F0UgtnkXdOtnJBbg-8LtpHs0vDZNOTiXYwzxcxbYxNtcsRjbA1qV_rVYsrpbC3Wlu2bluvgINGqFw_Dly7eT1V_dpGHcc70vcvYdiaTfxnOO9rUXpfzbcjQ4p_Z8zFTEPeT80GjHM2knddJxir8AX5-lbsVeXlyypAHACQYs4J_SuEM7O3hnm2htlbwxytIf8DJwWvtQ
Cites_doi 10.1002/ptr.v38.11
10.1186/s12943-019-1102-3
10.1038/s41408-024-01195-4
10.1186/s40364-022-00434-9
10.1038/nri3843
10.1016/j.biopha.2019.109570
10.1126/sciimmunol.adp3475
10.1016/j.smim.2015.11.003
10.1016/j.ebiom.2022.103941
10.1007/s12185-020-02827-8
10.1016/j.biopha.2023.114870
10.1038/s41577-024-01101-w
10.1016/j.biopha.2017.10.043
10.1016/j.ymthe.2020.09.015
10.1142/S0192415X20500780
10.3389/fimmu.2024.1352805
10.1146/annurev-med-062315-120245
10.3390/nu10010091
10.3389/fimmu.2020.00176
10.1073/pnas.2023752118
10.3389/fimmu.2023.1101495
10.3390/ijms19071970
10.1038/s41423-020-0488-6
10.1016/j.canlet.2019.07.017
ContentType Journal Article
Copyright Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni.
Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni
Copyright_xml – notice: Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni.
– notice: Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2025.1537398
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_2aae19b576e744e9a55a0b66f4c1c5ec
PMC11983556
40213558
10_3389_fimmu_2025_1537398
Genre Journal Article
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IPNFZ
M48
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c422t-d5f2cdf6e329201fbcc1a22589edc06c71e15a4ac40cd345f9c28352dae18d363
IEDL.DBID DOA
ISSN 1664-3224
IngestDate Wed Aug 27 01:25:33 EDT 2025
Thu Aug 21 18:27:58 EDT 2025
Fri Apr 11 19:19:18 EDT 2025
Sun Apr 13 01:31:26 EDT 2025
Tue Jul 01 05:14:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Chinese medicine
untargeted metabolomics
proteomics
RNA-Seq
enhance immunity
temperature
adoptive cell therapy
Language English
License Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c422t-d5f2cdf6e329201fbcc1a22589edc06c71e15a4ac40cd345f9c28352dae18d363
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Jiawei Ling, Zhejiang University, China
Wenshe Sun, Qingdao University, China
Zhenzhen Yang, Peking University Third Hospital, China
Shang Zhihao, Nanjing University of Chinese Medicine, China
Edited by: Valentyn Oksenych, University of Bergen, Norway
OpenAccessLink https://doaj.org/article/2aae19b576e744e9a55a0b66f4c1c5ec
PMID 40213558
PQID 3188820098
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_2aae19b576e744e9a55a0b66f4c1c5ec
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11983556
proquest_miscellaneous_3188820098
pubmed_primary_40213558
crossref_primary_10_3389_fimmu_2025_1537398
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-03-27
PublicationDateYYYYMMDD 2025-03-27
PublicationDate_xml – month: 03
  year: 2025
  text: 2025-03-27
  day: 27
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2025
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Beavis (B3) 2016; 28
Jiang (B4) 2019; 462
Zhang (B24) 2018; 19
Tang (B22) 2024; 38
Albarrán (B6) 2024; 15
Wang (B19) 2020; 121
Gumber (B12) 2022; 77
Evans (B15) 2015; 15
Liu (B13) 2022; 10
Lee (B23) 2018; 10
Zhang (B2) 2020; 17
Hosen (B8) 2020; 111
Wang (B5) 2020; 11
Newick (B10) 2017; 68
Jiang (B21) 2017; 96
Wang (B18) 2020; 48
Zhang (B9) 2023; 14
Wagner (B11) 2020; 28
Epperla (B7) 2024; 14
Bird (B14) 2024; 24
Heintzman (B17) 2024; 9
Lu (B20) 2023; 163
Li (B1) 2019; 18
O’Sullivan (B16) 2021; 118
References_xml – volume: 38
  year: 2024
  ident: B22
  article-title: Ginsenoside Re inhibits non-small cell lung cancer progression by suppressing macrophage M2 polarization induced by AMPKα1/STING positive feedback loop
  publication-title: Phytother Res
  doi: 10.1002/ptr.v38.11
– volume: 18
  start-page: 16
  year: 2019
  ident: B1
  article-title: Harnessing tumor-associated macrophages as aids for cancer immunotherapy
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1102-3
– volume: 14
  start-page: 210
  year: 2024
  ident: B7
  article-title: Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
  publication-title: Blood Cancer J
  doi: 10.1038/s41408-024-01195-4
– volume: 10
  start-page: 86
  year: 2022
  ident: B13
  article-title: Strategies to enhance CAR-T persistence
  publication-title: biomark Res
  doi: 10.1186/s40364-022-00434-9
– volume: 15
  year: 2015
  ident: B15
  article-title: Fever and the thermal regulation of immunity: the immune system feels the heat
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3843
– volume: 121
  start-page: 9
  year: 2020
  ident: B19
  article-title: Antitumor effects of immunity-enhancing traditional Chinese medicine
  publication-title: BioMed Pharmacother
  doi: 10.1016/j.biopha.2019.109570
– volume: 9
  year: 2024
  ident: B17
  article-title: Subset-specific mitochondrial stress and DNA damage shape T cell responses to fever and inflammation
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.adp3475
– volume: 28
  start-page: 64
  year: 2016
  ident: B3
  article-title: Reprogramming the tumor microenvironment to enhance adoptive cellular therapy
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2015.11.003
– volume: 77
  start-page: 103941
  year: 2022
  ident: B12
  article-title: Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2022.103941
– volume: 111
  year: 2020
  ident: B8
  article-title: Chimeric antigen receptor T-cell therapy for multiple myeloma
  publication-title: Int J Hematol
  doi: 10.1007/s12185-020-02827-8
– volume: 163
  start-page: 11
  year: 2023
  ident: B20
  article-title: Ginsenoside Rb1 stabilized and paclitaxel/protopanaxadiol co-loaded nanoparticles for synergistic treatment of breast tumor
  publication-title: BioMed Pharmacother
  doi: 10.1016/j.biopha.2023.114870
– volume: 24
  year: 2024
  ident: B14
  article-title: Fever affects T cell fate
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-024-01101-w
– volume: 96
  year: 2017
  ident: B21
  article-title: Ginsenoside Rg3 enhances the anti- proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway
  publication-title: BioMed Pharmacother
  doi: 10.1016/j.biopha.2017.10.043
– volume: 28
  year: 2020
  ident: B11
  article-title: CAR T cell therapy for solid tumors: bright future or dark reality
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2020.09.015
– volume: 48
  year: 2020
  ident: B18
  article-title: Positive role of chinese herbal medicine in cancer immune regulation
  publication-title: Am J Chin Med
  doi: 10.1142/S0192415X20500780
– volume: 15
  year: 2024
  ident: B6
  article-title: Adoptive T cell therapy for solid tumors: current landscape and future challenges
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2024.1352805
– volume: 68
  year: 2017
  ident: B10
  article-title: CAR T cell therapy for solid tumors
  publication-title: Annu Rev Med
  doi: 10.1146/annurev-med-062315-120245
– volume: 10
  start-page: 15
  year: 2018
  ident: B23
  article-title: Deoxyschizandrin, isolated from schisandra berries, induces cell cycle arrest in ovarian cancer cells and inhibits the protumoural activation of tumour-associated macrophages
  publication-title: Nutrients
  doi: 10.3390/nu10010091
– volume: 11
  year: 2020
  ident: B5
  article-title: Adoptive cell therapy targeting neoantigens: A frontier for cancer research
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.00176
– volume: 118
  year: 2021
  ident: B16
  article-title: Fever supports CD8(+) effector T cell responses by promoting mitochondrial translation
  publication-title: Proc Natl Acad Sci U.S.A
  doi: 10.1073/pnas.2023752118
– volume: 14
  start-page: 13
  year: 2023
  ident: B9
  article-title: CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2023.1101495
– volume: 19
  start-page: 25
  year: 2018
  ident: B24
  article-title: Schisandra chinensis fructus and its active ingredients as promising resources for the treatment of neurological diseases
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms19071970
– volume: 17
  year: 2020
  ident: B2
  article-title: The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-020-0488-6
– volume: 462
  start-page: 23
  year: 2019
  ident: B4
  article-title: Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2019.07.017
SSID ssj0000493335
Score 2.3970428
Snippet Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved...
IntroductionFollowing the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA)...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1537398
SubjectTerms adoptive cell therapy
Apoptosis - drug effects
Biological Products - pharmacology
Chinese medicine
Coculture Techniques
enhance immunity
Hot Temperature
Humans
Immunology
Immunotherapy, Adoptive - methods
Jurkat Cells
K562 Cells
Neoplasms - immunology
Neoplasms - therapy
proteomics
T-Lymphocytes - drug effects
T-Lymphocytes - immunology
T-Lymphocytes - metabolism
temperature
untargeted metabolomics
Title Screening and mechanistic study of natural compounds that enhance T cell anti-tumor effects post-heat treatment
URI https://www.ncbi.nlm.nih.gov/pubmed/40213558
https://www.proquest.com/docview/3188820098
https://pubmed.ncbi.nlm.nih.gov/PMC11983556
https://doaj.org/article/2aae19b576e744e9a55a0b66f4c1c5ec
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiJZXoEWuxA2FxvEj8REQpeqBC620N8uPsXaRNqm62QP_npkkXe0iJC5ccsjTmW_smYm-fMPY--TbZKxRpcoJsEAJusSoCGUjKXmAJgCMbIvv5upWXS_0Yq_VF3HCJnngyXAXtfcgbMC0GBqlwHqtfRWMySqKqCHS6osxb6-Y-jnlvVJKPf0lg1WYvcir9XqL9WCtP-Ikb6RtDyLRKNj_tyzzT7LkXvS5fMaezmkj_zQN95g9gu6EPZ4aSf56zvofkfgzGIa47xJfA_3PO0ow81E_lveZjxKeeA8ikVMvpQ0fln7g0C0JeH7D6Rs-Xj6symG77u_5TPXgd_1mKGnN5jtW-gt2e_n15stVObdSKKOq66FMOtcxZQOSulOJHGIUHqdya_HFKhMbAUJ75aOqYpJKZxtJiK1OaPw2SSNfsqOu7-A147aOEpK3AVqrsgm-yl7IWKkm-NRkW7APD2Z1d5NihsNKg0BwIwiOQHAzCAX7TJbfnUlq1-MO9AE3-4D7lw8U7PwBN4ezg8zlO-i3G4crFpYQJJpasFcTjrtHYeUsSFy-YO0BwgdjOTzSrZajArcQFq2jzZv_Mfq37AlZhIhtdXPKjob7LZxhpjOEd6NT4_bbQvwGsPwB9Q
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Screening+and+mechanistic+study+of+natural+compounds+that+enhance+T+cell+anti-tumor+effects+post-heat+treatment&rft.jtitle=Frontiers+in+immunology&rft.au=Wang%2C+Zhaoyi&rft.au=Diao%2C+Zhongqi&rft.au=Zhang%2C+Yiyan&rft.au=Liu%2C+Jiangying&rft.date=2025-03-27&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=16&rft_id=info:doi/10.3389%2Ffimmu.2025.1537398&rft.externalDocID=PMC11983556
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon